103. Persistence on F/TDF for HIV Pre-exposure Prophylaxis: Insights from Real-world Evidence
Sign Up to like & getrecommendations! Published in 2020 at "Open Forum Infectious Diseases"
DOI: 10.1093/ofid/ofaa439.413
Abstract: Background: Daily F/TDF is highly effective for HIV pre-exposure prophylaxis (PrEP). Prior studies have found that women and people of younger age have lower adherence and lower persistence on PrEP, yet real-world evidence describing persistence… read more here.
Keywords: gilead sciences; sciences inc; prep; non persistence ... See more keywords
Genome Wide Analysis Reveals Host Genetic Variants that Associate with Reduction in Clostridium difficile Infection Recurrence (rCDI) in Patients Treated with Bezlotoxumab
Sign Up to like & getrecommendations! Published in 2017 at "Open Forum Infectious Diseases"
DOI: 10.1093/ofid/ofx163.941
Abstract: Abstract Background Bezlotoxumab (BEZ) and actoxumab (ACT) are monoclonal antibodies against C. difficile toxins B and A, respectively. Patients receiving a single infusion of BEZ alone or with ACT in the MODIFY I/II trials showed… read more here.
Keywords: merck inc; rcdi; hold stock; stock ... See more keywords
SAT0243 Incidence of thromboembolic events in the tofacitinib rheumatoid arthritis, psoriasis, psoriatic arthritis and ulcerative colitis development programmes
Sign Up to like & getrecommendations! Published in 2018 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2018-eular.3048
Abstract: Background: Tofacitinib is an oral Janus kinase (JAK) inhibitor that preferentially inhibits signalling by JAK3 and JAK1, with functional selectivity over JAK2. Potential increased risk of venous thromboembolic events (VTE) in patients (pts) with rheumatoid… read more here.
Keywords: shareholder; pfizer inc; inc employee; pfizer ... See more keywords
AB0827 IMPACT OF BASELINE BODY MASS INDEX ON THE EFFICACY AND SAFETY OF TOFACITINIB IN PATIENTS WITH PSORIATIC ARTHRITIS
Sign Up to like & getrecommendations! Published in 2020 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2020-eular.993
Abstract: Background: Obesity is highly prevalent in PsA (~45%)1 and is associated with a reduced response to TNF inhibitors.2 Tofacitinib is an oral Janus kinase inhibitor for the treatment of PsA. Objectives: This post hoc analysis… read more here.
Keywords: inc employee; pfizer inc; pfizer; shareholder pfizer ... See more keywords